KWP
ARTL icon

Keystone Wealth Partners’s Artelo Biosciences ARTL Stock Holding History

Keystone Wealth Partners’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$7K Buy
+56
New +$6.43K ﹤0.01% 26

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Keystone Wealth Partners's ARTL Position: Q1 2022 in Review

Keystone Wealth Partners opened a new position in Artelo Biosciences (ARTL) in Q1 2022: 56 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #26 among its holdings.

18 funds tracked by Wall St. Rank hold ARTL as of Q1 2022.

  • Keystone Wealth Partners held 56 shares of Artelo Biosciences worth $7K as of Q1 2022.
  • Artelo Biosciences was a new Keystone Wealth Partners position in Q1 2022.
  • Artelo Biosciences made up ﹤0.01% of Keystone Wealth Partners's portfolio in Q1 2022, its #26 holding.
  • 18 funds tracked by Wall St. Rank held Artelo Biosciences as of Q1 2022.

Based on Keystone Wealth Partners's 13F filing for Q1 2022, filed 29 Apr 2022.